Optimizing Dvl PDZ domain inhibitor by exploring chemical space.
Because of advances in the high-throughput screening technology, identification of a hit that can bind to a target protein has become a relatively easy task; however, in the process of drug discovery, the following hit-to-lead and lead optimization still remain challenging. In a typical hit-to-lead and lead optimization process, the analogues of the most promising hits are synthesized for the development of structure-activity relationship (SAR) analysis, and in turn, in the effort of optimization of lead compounds, such analysis provides guidance for the further synthesis. The synthesis processes are usually long and labor-intensive. In silico searching has becoming an alternative approach to explore SAR especially with millions of compounds ready to be screened and most of them can be easily obtained. Here, we report our discovery of 15 new Dishevelled PDZ domain inhibitors by using such an approach. In our studies, we first developed a pharmacophore model based on NSC668036, an inhibitor previously identified in our laboratory; based on the model, we then screened the ChemDiv database by using an algorithm that combines similarity search and docking procedures; finally, we selected potent inhibitors based on docking analysis and examined them by using NMR spectroscopy. NMR experiments showed that all the 15 compounds we chose bound to the PDZ domain tighter than NSC668036.
Shan
Jufang
J
Department of Structural Biology, St. Jude Children's Research Hospital, 322 N. Lauderdale St., MS #311, Memphis, TN 38105, USA.
Zheng
Jie J
JJ
D048868:Adaptor Proteins, Signal Transducing / Q000037:antagonists & inhibitors*; D000072261:Dishevelled Proteins; D008958:Models, Molecular; D019906:Nuclear Magnetic Resonance, Biomolecular; D054731:PDZ Domains; D010750:Phosphoproteins / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
D048868:Adaptor Proteins, Signal Transducing; D000072261:Dishevelled Proteins; D010750:Phosphoproteins
J Chem Inf Model. 2005 Jan-Feb;45(1):160-9
15667141
J Am Chem Soc. 2003 Oct 8;125(40):12074-5
14518976
Biochem Biophys Res Commun. 2004 Sep 10;322(1):326-32
15313210
J Biomol NMR. 1995 Nov;6(3):277-93
8520220
Cancer Res. 2007 Jan 15;67(2):573-9
17234765
Dev Cell. 2002 Apr;2(4):449-61
11970895
Nat Rev Drug Discov. 2006 Dec;5(12):997-1014
17139285
Nat Rev Drug Discov. 2003 May;2(5):369-78
12750740
Drug Discov Today. 2006 Aug;11(15-16):741-8
16846802
J Med Chem. 2004 Mar 25;47(7):1739-49
15027865
Biochemistry. 2003 Jun 17;42(23):7068-76
12795602
J Chem Inf Model. 2005 Jan-Feb;45(1):177-82
15667143
Curr Opin Chem Biol. 1997 Jun;1(1):72-8
9667842
Angew Chem Int Ed Engl. 2006 Jun 2;45(23):3790-5
16671149
Chem Biol. 2006 Dec;13(12):1247-51
17185220
Proteins. 1999 Nov 1;37(2):228-41
10584068
Protein Eng. 1995 Feb;8(2):127-34
7630882
Nat Rev Drug Discov. 2004 Dec;3(12):1047-56
15573103
Curr Opin Chem Biol. 2004 Jun;8(3):255-63
15183323
Am J Pharmacogenomics. 2004;4(4):263-76
15287820
Biochemistry. 2005 Nov 29;44(47):15495-503
16300398
J Mol Med (Berl). 2005 Dec;83(12):955-63
16283145
Mol Cell. 2003 Nov;12(5):1251-60
14636582